United Therapeutics
UTHR
625 hedge funds and large institutions have $15.7B invested in United Therapeutics in 2024 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 207 increasing their positions, 227 reducing their positions, and 48 closing their positions.
129% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 48
10% more funds holding
Funds holding: 568 → 625 (+57)
7% more capital invested
Capital invested by funds: $14.6B → $15.7B (+$1.03B)
9% less repeat investments, than reductions
Existing positions increased: 207 | Existing positions reduced: 227
5.28% less ownership
Funds ownership: 103.58% → 98.31% (-5.3%)
6% less funds holding in top 10
Funds holding in top 10: 18 → 17 (-1)
32% less call options, than puts
Call options by funds: $74.3M | Put options by funds: $110M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$130M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$106M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$83.8M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$68.5M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
+$54.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$499M |
| 2 |
Amundi
Paris,
France
|
-$138M |
| 3 |
Morgan Stanley
New York
|
-$137M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
-$64.1M |
| 5 |
BlackRock
New York
|
-$51.2M |
UTHR Hedge Fund Activity: Q3 2024 in Review
625 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2024, worth a combined $15.7B — up 7.1% from $14.6B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new UTHR positions and 48 closed out — a net gain of 62 holders — while 207 added to existing stakes and 227 trimmed.
The largest buyer was Norges Bank, adding an estimated $130M. The largest seller was Citigroup, cutting an estimated $499M.
- 625 institutional investors held United Therapeutics (UTHR) as of Q3 2024, up from 568 in Q2 2024.
- Funds reported $15.7B of United Therapeutics stock for Q3 2024, up 7.1% quarter-over-quarter.
- 110 funds opened new United Therapeutics positions in Q3 2024 and 48 closed out, a net change of +62 holders.
- The largest United Therapeutics buyer in Q3 2024 was Norges Bank, an estimated $130M added.
- The largest United Therapeutics seller in Q3 2024 was Citigroup, an estimated $499M sold.
Based on aggregated 13F filings for Q3 2024.